Colby Suire - Talaris Therapeutics Head RD
| TALSDelisted Stock | USD 2.98 0.10 3.25% |
Insider
Colby Suire is Head RD of Talaris Therapeutics
| Phone | 502 398 9250 |
| Web | https://talaristx.com |
Talaris Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2281) % which means that it has lost $0.2281 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4164) %, meaning that it created substantial loss on money invested by shareholders. Talaris Therapeutics' management efficiency ratios could be used to measure how well Talaris Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Talaris Therapeutics currently holds 2.88 M in liabilities with Debt to Equity (D/E) ratio of 0.02, which may suggest the company is not taking enough advantage from borrowing. Talaris Therapeutics has a current ratio of 28.34, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Talaris Therapeutics' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Michael Carruthers | Edgewise Therapeutics | 66 | |
| Nicole White | Assembly Biosciences | N/A | |
| Kerry Whalen | Cullinan Oncology LLC | N/A | |
| Malinda Longphre | Connect Biopharma Holdings | N/A | |
| Jennifer Michaelson | Cullinan Oncology LLC | 57 | |
| BA CPA | Adicet Bio | 50 | |
| Susannah Walpole | Spero Therapeutics | N/A | |
| Tania Philipp | Vor Biopharma | 52 | |
| Thomas Templeman | Nuvation Bio | 60 | |
| MD FACP | NextCure | 71 | |
| MBA BS | CytomX Therapeutics | 45 | |
| Aya Jakobovits | Adicet Bio | 69 | |
| Uri MD | Assembly Biosciences | 52 | |
| James Brady | Spero Therapeutics | N/A | |
| Karl MD | Achilles Therapeutics PLC | 57 | |
| Ian Critchley | Spero Therapeutics | N/A | |
| SPHR SHRMSCP | Ovid Therapeutics | N/A | |
| Zoology Dphil | Ovid Therapeutics | 69 | |
| Sumita JD | Instil Bio | 50 | |
| Kim Blickenstaff | Nuvation Bio | 68 | |
| Jason MBA | Ovid Therapeutics | 46 | |
Management Performance
| Return On Equity | -0.42 | |||
| Return On Asset | -0.23 |
Talaris Therapeutics Leadership Team
Elected by the shareholders, the Talaris Therapeutics' board of directors comprises two types of representatives: Talaris Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Talaris. The board's role is to monitor Talaris Therapeutics' management team and ensure that shareholders' interests are well served. Talaris Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Talaris Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Nancy MD, Chief Officer | ||
| Eric Gornstein, Head Planning | ||
| Suzanne Tollerud, VP Devel | ||
| Michael Zdanowski, Chief Officer | ||
| JD LLB, CEO and President | ||
| Suzanne MD, Member Founder | ||
| Mary Fenton, CFO Treasurer | ||
| Farah Natoli, Head Management | ||
| Colby Suire, Head RD | ||
| Andrew Farnsworth, Chief Officer |
Talaris Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Talaris Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.42 | |||
| Return On Asset | -0.23 | |||
| Current Valuation | (28.92 M) | |||
| Shares Outstanding | 42.81 M | |||
| Shares Owned By Insiders | 11.90 % | |||
| Shares Owned By Institutions | 77.67 % | |||
| Number Of Shares Shorted | 340.1 K | |||
| Price To Book | 0.28 X | |||
| EBITDA | (74.31 M) | |||
| Net Income | (73.89 M) |
Thematic Opportunities
Explore Investment Opportunities
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Other Consideration for investing in Talaris Stock
If you are still planning to invest in Talaris Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Talaris Therapeutics' history and understand the potential risks before investing.
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. |